Skip to main content

Publications

Found 182 results
Author Title [ Year(Asc)]
Filters: Filter is   [Clear All Filters]
2013
Payne BA, Kyle PM, Lim K, Lisonkova S, Magee LA, Pullar B, et al.. An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens. 2013;3(3):166-71.  (232.97 KB)
Seuc A, Peregoudov A, Betrán A, Gulmezoglu A. Intermediate outcomes in randomized clinical trials: an introduction. Trials. 2013;14:78.  (478.57 KB)
Bickford C, Magee LA, Mitton C, Kruse M, Synnes A, Sawchuck D, et al.. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res. 2013;13:527.  (2 MB)
Firoz T, Chou D, von Dadelszen P, Agrawal P, Vanderkruik R, Tunçalp Ö, et al.. Measuring maternal health: focus on maternal morbidity. Bull World Health Organ. 2013;91(10):794-6.  (660.26 KB)
Payne BA, Hodgson S, Hutcheon J, Joseph KS, Li J, Lee T, et al.. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8.  (85.31 KB)
Lalani S, Firoz T, Magee LA, Sawchuck D, Payne BA, Gordon R, et al.. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.  (529.81 KB)
von Dadelszen P, Sawchuck D, Hofmeyr J, Magee LA, Bracken H, Mathai M, et al.. PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. Pregnancy Hypertens. 2013;3(4):199-202.  (183.96 KB)
Magee LA, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351.  (447.63 KB)
De Silva D, Halstead A, Côté A-M, Sabr Y, von Dadelszen P, Magee LA. Random urine albumin:creatinine ratio in high-risk pregnancy - Is it clinically useful?. Pregnancy Hypertens. 2013;3(2):112-4.  (189.28 KB)
Staff A, Benton S, von Dadelszen P, Roberts J, Taylor R, Powers R, et al.. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61(5):932-42.  (529.57 KB)
De Silva D, Halstead A, Côté A-M, Sabr Y, von Dadelszen P, Magee LA. Unexpected random urinary protein:creatinine ratio results-limitations of the pyrocatechol violet-dye method. BMC Pregnancy Childbirth. 2013;13:152.  (834.74 KB)
Bell M, Roberts J, Founds S, Jeyabalan A, Terhorst L, Conley Y. Variation in endoglin pathway genes is associated with preeclampsia: a case-control candidate gene association study. BMC Pregnancy Childbirth. 2013;13:82.  (404.09 KB)
2011
Kozic J, Benton S, Hutcheon J, Payne BA, Magee LA, von Dadelszen P. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004.  (280.12 KB)
Tsigas E, Magee LA. Advocacy organisations as partners in pre-eclampsia progress: patient involvement improves outcomes. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):523-36.  (438.09 KB)
Payne BA, Magee LA, von Dadelszen P. Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62.  (178.71 KB)
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
Magee LA, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane J, et al.. Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529.  (298.54 KB)
Millman A, Payne BA, Qu Z, M Douglas J, Hutcheon J, Lee T, et al.. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714.  (383.37 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
Firoz T, Sanghvi H, Merialdi M, von Dadelszen P. Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):537-48.  (309.47 KB)
Laskin S, Payne BA, Hutcheon J, Qu Z, M Douglas J, Ford J, et al.. The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8.  (370.8 KB)
Magee LA, Lowe S, M Douglas J, Kathirgamanathan A. Therapeutics and anaesthesia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):477-90.  (187.9 KB)
Yen T-W, Payne BA, Qu Z, Hutcheon J, Lee T, Magee LA, et al.. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809.  (269.78 KB)
2010
Steegers E, von Dadelszen P, Duvekot J, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-44.  (809.94 KB)
2008
Magee LA, Helewa M, Rey E. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl):S1-S2.  (1.73 MB)

Pages